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A b s t r a c t
Introduction: Coronary artery disease is nowadays responsible for approximately 15% of hospitalizations in Poland. Minimally 
invasive coronary artery bypass (MIDCAB) represents an attractive alternative to a sternotomy, and at the same time provides better 
life quality and facilitates quick rehabilitation.
Aim: To evaluate whether MIDCAB can be performed with similar early and mid-term results as off-pump coronary artery bypass 
(OPCAB) and therefore can be considered as a safe stage in hybrid revascularization.
Material and methods: In a retrospective cohort study, we analyzed 73 consecutive patients who underwent coronary artery 
bypass grafting (left internal mammary artery to left anterior descending artery) between 2013 and 2016 in the Department of 
Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow. Thirty-eight (52.1%) MIDCAB and 35 (47.9%) OPCAB 
patients were enrolled.
Results: Short-term results did not significantly differ between groups and similar 30-day mortality was observed (MIDCAB 2.6% 
vs. OPCAB 2.9%, p = 1). The median follow-up period was 21 months. There were no statistical differences in terms of overall sur-
vival or cardiac mortality between groups (94.7% vs. 88.6%, p = 0.42; 2.6% vs. 2.9%, p = 1, respectively). The rate of hospitalization 
due to cardiac causes was similar in both groups (7.9% vs. 5.1%, p = 1) and there were no differences in current exacerbation of 
angina or heart failure, with median NYHA class I and CCS class I in both groups.
Conclusions: Despite higher technical difficulty, MIDCAB procedures can be performed with similar safety results as OPCAB 
procedures. No differences in terms of mortality, repeat revascularization or recurrent angina are observed.
Key words: myocardial revascularization, coronary artery disease, coronary artery bypass grafting surgery, minimally invasive 
coronary artery bypass, long-term survival, hybrid revascularization.
Introduction 
Coronary artery disease (CAD) is nowadays responsi-
ble for approximately 15% of hospitalizations in Poland. 
Despite improvement in epidemiology in the last two 
decades, the early mortality rate (below 65 years old) is 
still high for these patients, and CAD remains the leading 
cause of death in developed countries. 
According to the European Society of Cardiology 
(ESC) guidelines, revascularization in multivessel stable 
CAD with proximal left anterior descending (LAD) artery 
involvement is recommended as the best treatment op-
tion, and coronary artery bypass grafting (CABG) proves 
to be beneficial over percutaneous coronary intervention 
(PCI) in terms of recurrent angina and repeat revascular-
ization [1–3]. The traditional approach for CABG involves 
a  median sternotomy and supplying narrowed arteries 
with arterial or venous grafts, as it is described else-
where [4]. In the case of proximal LAD stenosis, the best 
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treatment option includes using left internal mammary 
artery (LIMA), which has been proved to diminish ear-
ly postoperative mortality and has excellent both short 
and long-term results in all age groups, including elder 
and diabetic patients [5, 6]. Nevertheless, the traditional 
CABG procedure, where cardiopulmonary bypass (CPB) 
is required, may carry an increased risk of postoperative 
complications in high-risk patients. Therefore, searching 
for innovative methods of treatment to diminish the 
risk of surgery and maintain the benefits of LIMA use is 
warranted. With observed development in both cardiac 
surgery and invasive cardiology, a promising alternative 
to combine surgical and percutaneous approaches into 
a hybrid procedure in order to perform complete revascu-
larization arises. Such a method should provide optimal 
safety and efficacy of revascularization in the most ardu-
ous and complicated cases to both specialties. 
Minimally invasive coronary artery bypass (MIDCAB) 
allows a LIMA to LAD graft to be performed without CPB, 
and represents an attractive alternative to a  sternoto-
my, as it is proved to provide better life quality and ease 
quick rehabilitation [7, 8]. MIDCAB procedures are usual-
ly performed through a left anterolateral minithoracoto-
my with an incision of 5- to 6-cm in length. Then, the pec-
toralis muscle is displaced bluntly and the ribs are spread 
with the retractor. Despite higher technical difficulty as 
the smaller surgical field results in lower visibility, this 
approach allows one to retain the sternum intact (Figures 
1 A, B). Therefore, similar safety and efficacy, and mark-
edly reduced post-operative length of stay, when com-
pared to conventional off-pump CABG (OPCAB), are very 
promising. Nevertheless, the studies concerning graft 
patency and mortality reduction after LIMA graft implan-
tation included only patients who were operated on via 
median sternotomy, and similar results can only be sus-
pected for other approaches. 
Aim
The aim of the study is to evaluate whether MIDCAB 
can be performed with similar early and mid-term results 
as OPCAB and therefore may be considered as a poten-
tial stage in hybrid revascularization. 
Material and methods
In a retrospective cohort study, we analyzed 73 con-
secutive patients with single-vessel disease who un-
derwent off-pump CABG (LIMA to LAD) between 2013 
and 2016 in the Department of Cardiovascular Surgery 
and Transplantology (38 (52.1%) MIDCAB vs. 35 (47.9%) 
OPCAB). Data were obtained from patient medical re-
cords. Follow-up data were obtained as a part of outpa-
tient clinic appointment.
All MIDCAB procedures were performed through a left 
anterolateral minithoracotomy. After making a 5- to 6-cm 
skin incision in the fifth intercostal space, the pectoralis 
muscle was displaced bluntly with minimal division fol-
lowing the muscle fiber orientation. The OPCAB proce-
dures were performed through a median sternotomy. In 
all of the cases, LIMA was harvested under direct vision, 
and anastomoses were performed using a vacuum stabi-
lizer, without CPB.
Postoperative complications were assessed, including 
30-day mortality, MACCE (defined as any postoperative 
myocardial infarction (MI), death from cardiac causes 
and acute stroke), deep wound infection, and need for 
re-exploration for bleeding and blood products transfu-
sions. Moreover, intensive care unit (ICU) stay and overall 
hospitalization time were also analyzed.
Follow-up data regarding all-cause and cardiac mor-
tality was obtained from Ministry of the Interior and Ad-
ministration. The follow-up questionnaire included cur-
rent CCS and NYHA class, hospitalization due to cardiac 
causes, requirement for repeated revascularization (PCI 
or CABG), MI, and stroke. 
Statistical analysis
Statistical analysis was performed using Statistica 
software, version 12.0. In order to confirm a normal dis-
tribution of continuous variables, the Shapiro-Wilk test 
was used. Results were presented based on the param-
Figure 1. A – Intraoperative view. B – Incision site 14 days after surgery
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eters of descriptive statistics, including mean values and 
its standard deviations, or median values and its quar-
tiles, as appropriate. Categorical variables were present-
ed as percentages. Continuous variables were compared 
via Student’s t-test and categorical variables via the c2 
test or Fisher’s exact test as appropriate. Kaplan-Meier 
survival curves and log-rank tests were used in order 
to compare follow up all-cause and cardiac mortality. 
A p-value less than 0.05 was considered significant.
Results
Most of the operated patients were male (67.1%), with 
a mean age of 64.6 ±9.7 years. Patients included in the 
study had low perioperative risk (median EuroSCORE II 
0.8% 0.64–1.25) and preserved left ventricular ejection 
fraction (LVEF) (median 55% 50–60). The study groups 
did not differ significantly in terms of baseline charac-
teristics, including the perioperative risk, medical history 
of cardiovascular diseases, exacerbation of angina, and 
heart failure assessed on admission, and other comor-
bidities (Table I).
The median procedure time was significantly lower in 
the MIDCAB group (177.5 vs. 120 min, p = 0.04). Multivar-
iate stepwise regression and subgroup analysis showed 
that none of the preoperative parameters influenced the 
MIDCAB procedure time. However, older age and higher 
EuroSCORE II prolonged OPCAB surgery (p < 0.01).
Short-term results did not significantly differ between 
groups and similar 30-day mortality was observed (2.6% 
vs. 2.9%, p = 1). In the MIDCAB group, one of the patients 
had sudden cardiac arrest, which occurred after hospital 
discharge. The patient, however, had a high perioperative 
risk due to impaired LVEF (23% assessed by cardiac MRI). 
In the OPCAB group, sepsis and sternal dehiscence treat-
ed with a vacuum-assisted closure device were observed 
in one of the patients and the course was complicated 
with fatal right ventricle rupture. 
Within the early postoperative period, only 1 case 
of MI occurred in the MIDCAB group and early graft oc-
clusion was diagnosed without a  fatal outcome. Deep 
wound infection was observed in 2 individuals who un-
derwent OPCAB. Two cases of re-exploration for bleed-
ing were reported in the MIDCAB group. One was due to 
pleural hematoma and the other due to LIMA graft bleed-
ing. In spite of no differences in the chest tube drainage 
volume, packed red blood cells (PRBC) were transfused 
more often in the OPCAB group (p = 0.05) (Table II). 
The only factor influencing the incidence of postoper-
ative complications in the whole study group was chronic 
kidney disease (CKD) (p = 0.007).
Follow-up data regarding all-cause and cardiac mor-
tality were obtained from all of the patients. The median 
follow-up period was 21 months. There were no signif-
icant differences in terms of overall survival or cardiac 
mortality between groups (Figures 2, 3).
Table I. Baseline characteristics
Variable MIDCAB
(n = 38)
OPCAB
(n = 35)
P-value
Age [years] 62.92 ±9.85 66.43 ±9.33 0.12
Male sex, n (%) 26 (68.42) 23 (65.71) 0.81
BMI [kg/m2] 27.78 ±3.43 28.34 ±5.1 0.58
Diabetes, n (%) 10 (26.32) 13 (37.14) 0.32
Hypertension, n (%) 35 (92.11) 35 (100) 0.24*
Hyperlipidemia, n (%) 14 (36.84) 15 (42.86) 0.6
Atrial fibrillation, n (%) 2 (5.26) 2 (5.71) 1*
COPD, n (%) 0 (0) 1 (2.86) 0.48*
CKD, n (%) 0 (0) 3 (8.57) 0.11*
PAD, n (%) 3 (7.89) 4 (11.43) 0.7*
LVEF (%) 55 (50–60) 53 (48–60) 0.74
EuroSCORE II 0.73 (0.61–0.95) 1.12 (0.64–1.42) 0.55
Previous MI, n (%) 23 (60.53) 21 (60) 0.96
Previous PCI, n (%) 16 (42.11) 17 (48.57) 0.58
Previous stroke, n (%) 3 (7.89) 3 (8.57) 1*
Data shown as mean ± SD or as median (IQR), or number (percentage). 
BMI – body mass index, COPD – chronic obstructive pulmonary disease, 
CKD – chronic kidney disease, PAD – peripheral artery disease, LVEF – left ven-
tricle ejection fraction, MI – myocardial infarction, PCI – percutaneous coronary 
intervention. *Fisher’s exact test.
Table II. Postoperative complications
Variable MIDCAB
(n = 38)
OPCAB
(n = 35)
P-value
30-day mortality, 
n (%)
1 (2.63) 1 (2.86) 1*
MI, n (%) 1 (2.63) 0 (0) 1*
MACCE, n (%) 2 (5.26) 1 (2.86) 1*
Deep wound  
infection, n (%)
0 (0) 2 (5.71) 0.23*
Re-exploration for 
bleeding, n (%)
2 (5.26) 0 (0) 0.49*
PRBC transfusions, 
n (%)
4 (10.53) 10 (28.57) 0.05
FFP transfusions, 
n (%)
6 (15.79) 3 (8.57) 0.48*
PLT transfusions, 
n (%)
1 (2.63) 3 (8.57) 0.34*
24-hour post-surgery 
chest tube output 
volume [ml]
495 (380–730) 560 (400–760) 0.35
ICU stay [days] 1 (1–1) 1 (1–2) 0.27
Hospital stay [days] 8 (7–9) 8 (8–9) 0.11
Data shown as median (IQR), or number (percentage). MI – myocardial infarc-
tion, MACCE – major adverse cardiac and cerebrovascular event, PRBC – packed 
red blood cells, FFP – fresh frozen plasma, PLT – platelets, ICU – intensive care 
unit. *Fisher’s exact test.
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The rate of hospitalization due to cardiac causes was 
similar in both groups and there were no differences in 
current exacerbation of angina or heart failure, with me-
dian NYHA class I and CCS class I in both groups (Table III).
Discussion
Minimally invasive approaches have been of interest 
to many surgeons recently as general advantages include 
quick rehabilitation and superior cosmetic results [9]. 
Low perioperative mortality comparable to conventional 
off-pump technique has been previously reported [10], 
which is consistent with the study findings. Neverthe-
less, the most appealing benefits consist of lowering 
the incidence of expensive complications, such as deep 
wound infection and sternal dehiscence [9], which in the 
study were observed only in the OPCAB group. Aside from 
newly instituted hemodialysis, these complications have 
been determined to highly increase the surgery cost, up 
to $56,003 in the American study and €36.261 in the Eu-
ropean one [11, 12]. In contrast, surgical site infections 
after minimally invasive surgery are usually superficial 
and occur mostly in obese and female patients when 
the pressure placed on the wound edges by the retractor 
leads to tissue necrosis [13, 14].
Furthermore, prospective observation of graft paten-
cy in patients undergoing multi-vessel revascularization 
through a  minimally invasive approach revealed sig-
nificantly lower rates for grafts other than LIMA to LAD 
[15]. This leads to the hypothesis that a hybrid approach 
combining minimally invasive LIMA to LAD graft with PCI 
to other diseased arteries constitutes one area where 
MIDCAB procedures may find their greatest technical ap-
proachability, best patency results, and potentially high-
est institutional applicability. The MIDCAB is an especially 
attractive alternative for high-risk patients who would be 
disqualified from conventional CABG surgery and in whom 
complete revascularization using PCI might be technically 
difficult. It is a well stated fact that multivessel CAD itself 
is associated with lower rates of successful percutaneous 
revascularization, an increased number of complications 
and consequently with worse in-hospital and long-term 
outcomes [16]. Moreover, the risk seems to rise together 
with the atherosclerosis progression and calcification, es-
pecially in the scope of the left main coronary artery [17]. 
Nevertheless, MIDCAB procedures have additional 
relative contraindications, such as pulmonary disorders, 
 0 5 10 15 20 25 30 35 40 45 50 55
Time [months]
Number at risk
MIDCAB 37 32 27 22 15 8 2 0 0 0 0 
OPCAB 35 32 30 28 22 17 15 15 10 3 0
 MIDCAB        OPCAB
Figure 3. Freedom from cardiac mortality. Log-rank 
test p > 0.05
Table III. Follow-up data
Variable MIDCAB
(n = 38)
OPCAB
(n = 35)
P-value
All-cause mortality, n (%) 2 (5.26) 4 (11.43) 0.42*
Cardiac mortality, n (%) 1 (2.63) 1 (2.86) 1*
Hospitalization due to 
cardiac causes, n (%)
3 (7.89) 2 (5.71) 1*
MI, n (%) 0 (0) 0 (0) 1*
PCI, n (%) 1 (3.13) 0 (0) 1*
Cardiac surgery, n (%) 0 (0) 0 (0) 1*
Stroke, n (%) 0 (0) 0 (0) 1*
Data shown as number (percentage). MI – myocardial infarction, PCI – percuta-
neous coronary intervention. *Fisher’s exact test.
Su
rv
iv
al
 p
ro
ba
bi
lit
y
Fr
ee
do
m
 f
ro
m
 c
ar
di
ac
 m
or
ta
lit
y
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
 0 5 10 15 20 25 30 35 40 45 50 55
Time [months]
Number at risk
MIDCAB 37 32 27 22 15 8 2 0 0 0 0 
OPCAB 35 32 30 28 23 17 15 15 10 3 0
 MIDCAB        OPCAB
Figure 2. Survival probability. Log-rank test p > 0.05
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as they require intraoperative single-lung ventilation. Al-
though most studies do not report prolonged mechanical 
ventilation after MIDCAB and in some centers extubation 
in the operating room is routinely performed [18], in the 
randomized STET trial significantly worse lung function 
at discharge was observed in the minimally invasive ap-
proach group [19]. However, in our center patients are 
usually reintubated after surgery and the endotracheal 
tube is changed to a single-lumen tube. Next, mechanical 
ventilation is implemented following the same protocol 
as for the OPCAB procedure. This resulted in no differ-
ences observed for the ICU stay and therefore the overall 
hospitalization time.
However, despite all the advantages, the minimally 
invasive approach encounters technical difficulties that 
require highly trained surgical skills. Re-exploration for 
bleeding is therefore more commonly reported after MID-
CAB in most of the studies [9, 13, 19]. Furthermore, al-
though immediate and 6-month patency rates assessed 
by angiography do not decline below 94% and are sim-
ilar to those observed after on-pump CABG, the safety 
of the minimally invasive procedure, especially in terms 
of non-inferior long-term graft patency, remains unclear 
[20–22]. The present study is one of the first to describe 
the follow-up data in patients after minimally invasive 
surgical revascularization. Consistent with other reports, 
the study presented excellent outcomes with low cardi-
ac mortality and repeat revascularization rate [23, 24]. 
Moreover, the results were comparable to those observed 
for the OPCAB cohort with similar perioperative risk. 
The major consideration regarding the study is the 
small sample size coming from single-center experience. 
Moreover, since minimally invasive revascularization has 
been recently introduced in our center as a method of 
choice in eligible patients with single-vessel LAD dis-
ease, a limited group of patients with limited follow-up 
data was available. Although higher risk assessed by the 
EuroSCORE II was not an exclusion criterion and patients 
were analyzed consecutively, it is worth noting that the 
cohort presented low estimated periprocedural risk and 
therefore conclusions regarding more complex cases should 
be drawn with caution, especially in terms of considering 
MIDCAB as a stage in hybrid revascularization in high-risk 
patients with multivessel disease, when the expected com-
plication rate would be higher. The study results evidence 
only that MIDCAB procedures can be performed with sim-
ilar results as OPCAB; however, no direct conclusions prov-
ing the safety and efficacy of hybrid complete revascular-
ization combining MIDCAB LIMA : LAD and PCI with other 
diseased arteries may be drawn. Further prospective study 
to investigate this approach is warranted.
Conclusions
Despite higher technical difficulty, MIDCAB proce-
dures can be performed with similar safety as OPCAB 
procedures. No differences in terms of mid-term mortal-
ity, repeat revascularization or recurrent angina are ob-
served. Nevertheless, the actual long-term graft patency 
in this technique is still to be determined.
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